ZYME insider trading
NasdaqGS HealthcareZymeworks Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Zymeworks Inc.
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Company website: www.zymeworks.com
ZYME insider activity at a glance
FilingIQ has scored 252 insider transactions for ZYME since Aug 2, 2018. The most recent filing in our index is dated Apr 9, 2026.
Across the full history, 51 open-market purchases
and 69 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ZYME insider trades is 54.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ZYME Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding ZYME
Frequently asked
- How many insider trades does FilingIQ track for ZYME?
- FilingIQ tracks 252 Form 4 insider transactions for ZYME (Zymeworks Inc.), covering filings from Aug 2, 2018 onwards. 9 of those were filed in the last 90 days.
- Are ZYME insiders net buyers or net sellers?
- Across the full Form 4 history for ZYME, 51 transactions (20%) were open-market purchases and 69 (27%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ZYME insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is ZYME in?
- Zymeworks Inc. (ZYME) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.84B.
Methodology & sources
Every ZYME insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.